Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Skip Level Meetings: Prepare, Purpose, Pitfalls
Summary
In this episode, Paul Ward, head of field medical at BeiGene, joins Tom Caravela to delve into the concept of skip level meetings. Paul shares insights on who should initiate these meetings and their objectives, emphasizing the importance of effective communication. The discussion covers preparation strategies for MSLs, potential benefits for leaders, and advice on avoiding common pitfalls. Paul also provides guidance on making a positive impression in informal settings and navigating group dynamics. The episode wraps up with practical advice for both MSLs and leaders, alongside a mention of Momentum Events and a discount code.
My guest today is Paul Ward, Head of Field Medical Oncology and Hematology at BeiGene and MSL Society Advisory Board Member and we discuss the pros and cons of “Skip Level” meetings.
This episode is sponsored by Momentum Events and their upcoming Medical Affairs Xcellence Summit, October 13-14 in Philadelphia. For more details, visit: https://bit.ly/3zFol58 and use discount code TOM20 to get a 20% discount on your registration! Early Bird Registration expires on August 26th.
Paul shares…
👉 What the term “Skip Level Meeting” means
👉 Who initiates these meetings
👉 What the goal or purpose of these meetings is
👉 What preparation is involved for both the leaders and the MSLs
👉 What positives come from these meetings
👉 What the dangers are that can result from these meetings
👉 Advice for MSLs and employees who participate in the meetings
Skip Level Meetings, Medical Science Liaison, Paul Ward BeiGene, Medical Affairs Xcellence Summit, Momentum Events
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO